• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ProSomnus Inc.

    2/14/24 11:10:52 AM ET
    $OSA
    Medical Specialities
    Health Care
    Get the next $OSA alert in real time by email
    SC 13G 1 walleye-osaaw123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    ProSomnus, Inc.

    (Name of Issuer)

     

    Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share

    (Title of Class of Securities)

     

    50535E116

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  50535E116
     SCHEDULE 13G
    Page 2 of 6 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Walleye Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Minnesota
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    1,103,690
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    1,103,690
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,103,690
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.31%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

     

    CUSIP No.  50535E116
     SCHEDULE 13G
    Page 3 of 6 Pages

     

    Item 1.(a) Name of Issuer

    ProSomnus, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    5675 Gibraltar Drive

    Pleasanton, CA 94588

    Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    Walleye Capital LLC, a Minnesota limited liability company

    315 Park Ave. South

    New York, NY 10010

      

    Item 2.(d) Title of Class of Securities

    Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share

     

    Item 2.(e) CUSIP No.:

    50535E116

     

    CUSIP No.  50535E116
     SCHEDULE 13G
    Page 4 of 6 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No.  50535E116
     SCHEDULE 13G
    Page 5 of 6 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Person’s ownership of the Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share as of December 31, 2023, is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    The amount beneficially owned by the Reporting Person is determined based on 16,398,599 shares of common stock outstanding as of November 13, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No.  50535E116
     SCHEDULE 13G
    Page 6 of 6 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

     

     

     

    Walleye Capital LLC

           
      By:  /s/ Thomas Wynn
        Thomas Wynn, Global Chief Compliance Officer
           

     

           
    Get the next $OSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Kim Sung was granted 315,742 shares, increasing direct ownership by 157% to 516,808 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:20:29 PM ET
    $OSA
    Medical Specialities
    Health Care

    Dow Brian B was granted 315,742 shares, increasing direct ownership by 337% to 409,492 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:16:43 PM ET
    $OSA
    Medical Specialities
    Health Care

    Liptak Len was granted 1,322,756 shares, increasing direct ownership by 208% to 1,957,216 units (SEC Form 4)

    4 - ProSomnus, Inc. (0001934064) (Issuer)

    2/16/24 6:14:33 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

    PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L

    2/22/24 8:30:00 AM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    SEC Filings

    View All

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    5/8/24 9:25:27 AM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - ProSomnus, Inc. (0001934064) (Filer)

    4/30/24 4:51:50 PM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form 10-K/A filed by ProSomnus Inc. (Amendment)

    10-K/A - ProSomnus, Inc. (0001934064) (Filer)

    4/29/24 5:29:15 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ProSomnus Inc.

    SC 13G - ProSomnus, Inc. (0001934064) (Subject)

    2/14/24 11:10:52 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by ProSomnus Inc. (Amendment)

    SC 13G/A - ProSomnus, Inc. (0001934064) (Subject)

    2/12/24 11:46:53 AM ET
    $OSA
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by ProSomnus Inc. (Amendment)

    SC 13D/A - ProSomnus, Inc. (0001934064) (Subject)

    12/8/23 4:15:31 PM ET
    $OSA
    Medical Specialities
    Health Care

    $OSA
    Financials

    Live finance-specific insights

    View All

    ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results

    PLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin

    3/26/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call

    PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv

    3/15/24 8:01:20 PM ET
    $OSA
    Medical Specialities
    Health Care

    ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024

    PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc

    2/20/24 4:05:00 PM ET
    $OSA
    Medical Specialities
    Health Care